Scholar Rock Holding buy BiotechBee
Start price
08.09.24
/
80%
€7.55
Target price
31.01.27
€11.00
Performance (%)
421.85%
End price
14.12.24
€39.40
Summary
This prediction ended on 14.12.24 with a price of €39.40. With a performance of 421.85% the BUY prediction by BiotechBee was a big success. BiotechBee has 80% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Scholar Rock Holding | -3.093% | -3.093% | -10.048% |
| iShares Core DAX® | -1.764% | 2.259% | 15.847% |
| iShares Nasdaq 100 | -1.632% | -0.193% | 4.686% |
| iShares Nikkei 225® | -2.451% | 4.086% | 16.083% |
| iShares S&P 500 | -2.252% | -0.151% | 1.636% |
According to BiotechBee what are the pros and cons of Scholar Rock Holding for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Scholar Rock Holding diskutieren
Buy mit Kursziel 11,0